Corporate Statement

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Listening for Needs. Delivering Solutions. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future.

Investor Overview

News Releases

14 Apr '24
-- In recognition of 30 years of Extracorporeal Photopheresis Use for Chronic Graft vs. Host Disease (cGvHD), this year's grant is to be dedicated to research in cGvHD -- -- Investigators of ECP in cGvHD are invited to apply for €75,000 research grant -- DUBLIN, April 14, 2024 /PRNewswire/ --
11 Mar '24
– Retrospective analysis suggests Acthar Gel treatment was associated with similar improvement in health status and overall symptom reduction in African Americans and non-African Americans with symptomatic sarcoidosis 1 –    – Findings on treatment response and physician-reported outcomes indicate
go back to the top of the page